11/29/2007 9:45:18 AM
MINNEAPOLIS--(BUSINESS WIRE)--MGI PHARMA, INC. (NASDAQ:MOGN) a biopharmaceutical company focused in oncology and acute care, today stated that its board of directors has authorized management to evaluate possible strategic alternatives. To assist in this process, the company retained the services of Lehman Brothers, who is acting as its exclusive financial advisor. There can be no assurance that a strategic transaction will be pursued or consummated, and the company indicated that its strategy is yielding strong operating and financial performance.
comments powered by